Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E12.25 EPS (ttm)5.57 Insider Own0.33% Shs Outstand726.39M Perf Week-2.68%
Market Cap49.54B Forward P/E6.59 EPS next Y10.35 Insider Trans-0.49% Shs Float696.91M Perf Month-2.90%
Income4.16B PEG0.62 EPS next Q2.32 Inst Own76.30% Short Float1.83% Perf Quarter-21.76%
Sales14.73B P/S3.36 EPS this Y109.10% Inst Trans-0.58% Short Ratio2.13 Perf Half Y-12.65%
Book/sh6.92 P/B9.86 EPS next Y17.80% ROA8.70% Target Price107.90 Perf Year-36.97%
Cash/sh6.03 P/C11.32 EPS next 5Y19.80% ROE56.80% 52W Range66.62 - 110.20 Perf YTD-34.65%
Dividend- P/FCF11.85 EPS past 5Y25.80% ROI20.00% 52W High-38.11% Beta1.47
Dividend %- Quick Ratio2.00 Sales past 5Y18.70% Gross Margin96.40% 52W Low2.37% ATR2.18
Employees7467 Current Ratio2.10 Sales Q/Q18.40% Oper. Margin31.10% RSI (14)38.27 Volatility3.33% 3.01%
OptionableYes Debt/Eq4.17 EPS Q/Q24.00% Profit Margin19.60% Rel Volume0.88 Prev Close69.74
ShortableYes LT Debt/Eq4.06 EarningsJan 24 BMO Payout0.00% Avg Volume6.00M Price68.20
Recom2.10 SMA20-2.41% SMA50-9.40% SMA200-18.31% Volume5,249,246 Change-2.21%
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Feb-13-18Upgrade Barclays Equal Weight → Overweight $105
Jan-26-18Reiterated SunTrust Buy $127 → $139
Jan-05-18Downgrade BofA/Merrill Buy → Neutral
Dec-27-17Downgrade Bernstein Outperform → Mkt Perform
Dec-22-17Reiterated Stifel Buy $149 → $130
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Dec-13-18 10:13AM  Top 10 Healthcare Stories of 2018 Motley Fool
09:30AM  Biotech Companies in the News ACCESSWIRE
Dec-12-18 10:51AM  5 Pharma Stocks That Could Cure Ailing Portfolios in 2019 InvestorPlace
Dec-11-18 05:45PM  Celgene (CELG) Gains As Market Dips: What You Should Know Zacks
10:44AM  Has Celgene Entered Bargain Territory? GuruFocus.com
Dec-10-18 03:20PM  19 Best Stocks to Buy for 2019 Kiplinger
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
07:20AM  Report: Developing Opportunities within Avangrid, GoDaddy, NGL Energy Partners LP, Lazard, Briggs & Stratton, and Celgene Future Expectations, Projections Moving into 2019 GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Tesaro and Celgene ACCESSWIRE
Dec-09-18 04:46PM  Here's Why BeiGene Stock Rose 21.7% in November Motley Fool
Dec-08-18 10:56PM  Stocks That Fell to 3-Year Lows in the Week of Dec. 7 GuruFocus.com
06:02PM  Hedge Funds Are Dumping Celgene Corporation (CELG) Insider Monkey
05:36PM  Could These Be the Next 2 Biotech Buyouts? Motley Fool
08:00AM  These 3 Value Stocks Are Absurdly Cheap Right Now Motley Fool
Dec-07-18 01:32PM  Health Care Slides Midday, but Cannabis Stocks Soar Investing.com
Dec-06-18 01:48PM  3 Top Stocks After #ASH18 Motley Fool
Dec-05-18 04:32PM  This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger American City Business Journals
09:38AM  J&J's Blood Cancer Drugs Succeed in Label Expansion Studies Zacks
09:10AM  Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China Zacks
08:17AM  Can Celgene and bluebird bio Survive a Two-Pronged Attack? Motley Fool
Dec-04-18 04:58PM  J&J Strikes Deal with argenx to Co-Develop Cancer Antibody Zacks
10:30AM  J&J's multiple myeloma drug reduces risk of death in late-stage study Reuters
07:59AM  The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga
Dec-03-18 07:30PM  Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018 Business Wire
06:09PM  Celgene (CELG) Announces Various Cancer Data at ASH 2018 Zacks
05:45PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
03:50PM  5 Top Stock Trades for Tuesday: NFLX, AMD, SQ, QQQ InvestorPlace
01:32PM  UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients Reuters
Dec-02-18 07:35PM  Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018 Business Wire
07:30PM  bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Business Wire
06:57PM  High-cost Gilead cell therapy proves durable for some lymphoma patients Reuters
05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
05:00PM  Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session Business Wire
10:35AM  Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018 Business Wire
Dec-01-18 05:00PM  Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018 Business Wire
07:03AM  Top Biotech Stocks to Watch at ASH 2018 Motley Fool
Nov-30-18 03:28PM  8 Stocks to Buy for 2019 (and 5 to Sell) Kiplinger
03:26PM  3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 InvestorPlace
07:30AM  Good News Is on the Way for Blood Cancer Patients Barrons.com
07:00AM  Is It Time to Buy These Beaten-Up Bargains in Healthcare? Motley Fool
Nov-29-18 03:17PM  Is It Time to Buy Celgene? Motley Fool
Nov-28-18 10:15PM  The Black Swan That Could Sink Celgene Motley Fool
04:07PM  Celgene & Bluebird's CAR T Therapy Study Completes Enrollment Zacks
04:01PM  5 Top Stock Trades for Thursday: Alphabet and the Markets Rally InvestorPlace
12:47PM  3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer Investor's Business Daily
08:22AM  Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News Zacks
Nov-27-18 04:35PM  Why Celgene's Blockbuster Cancer Drug Looks Safe For Now Investor's Business Daily
02:39PM  Celgene Is Showing Us a Couple of Interesting Bullish Divergences TheStreet.com
07:30AM  Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma Business Wire
Nov-26-18 01:49PM  Jefferies: Buy Celgene, lowest P/E in history CNBC Videos
10:36AM  Celgene Stock Could Nearly Double, Analyst Says Barrons.com
09:29AM  These are the most beaten-up stocks right now that are overdue for a bounce, statistics show CNBC
Nov-25-18 09:35AM  9 Policy Catalysts For Health Care Investors To Watch Before Year's End Benzinga
09:00AM  Better Buy: Gilead Sciences vs. Celgene Motley Fool
Nov-22-18 05:45PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
Nov-21-18 11:30AM  Celgene Corporation (NASDAQ:CELG) Is Trading At A 41.11% Discount Simply Wall St.
Nov-20-18 04:24PM  Corcept Initiates Phase III Study for Cushing's Syndrome Zacks
07:51AM  2019 Should Mark the Return of Value Stocks Motley Fool
07:00AM  Today's Research Reports on Trending Tickers: Celgene and Tesaro ACCESSWIRE
Nov-19-18 08:46PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
04:13PM  3 High-Growth Stocks That Are Just Getting Started Motley Fool
02:18PM  The regulatory impact on biotech and health care stocks CNBC Videos
Nov-17-18 05:02PM  Better Buy: Celgene Corporation vs. Merck & Co. Motley Fool
02:18PM  Stocks That Fell to 3-Year Lows in the Week of Nov. 16 GuruFocus.com
08:31AM  My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy Motley Fool
Nov-15-18 05:45PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
Nov-14-18 04:13PM  [$$] Dragonfly Therapeutics Gets $50 Million Through Celgene Alliance The Wall Street Journal
03:56PM  10 Deeply Discounted Stocks to Buy Kiplinger
03:09PM  Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels MarketWatch
07:58AM  Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis PR Newswire
Nov-12-18 08:22AM  Why Celgene's Stock Nosedived in October Motley Fool
Nov-10-18 09:54AM  Biotech stocks have been hit hard here are ones analysts like best for a rebound MarketWatch
Nov-09-18 04:32PM  Waiting for bluebird bio to Sing at ASH Motley Fool
Nov-08-18 09:59AM  Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3 Zacks
Nov-07-18 09:16AM  3 Cancer Stocks to Watch in December Motley Fool
02:39AM  [$$] US midterm elections: key results and highlights Financial Times
Nov-06-18 07:04PM  Cramer's lightning round: This stock could recover if the... CNBC Videos
05:45PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
Nov-05-18 02:28PM  Biogen Stock Rebounds After Impressive Q3 Earnings InvestorPlace
02:25PM  Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates Zacks
Nov-03-18 04:52PM  3 Top Biotech Stocks With P/Es Below 14 Motley Fool
Nov-02-18 01:01PM  Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock Zacks
10:17AM  bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat Zacks
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Events Business Wire
Nov-01-18 09:50AM  Results from More Than 100 Abstracts Highlighting Celgene Pipeline Compounds and Therapies to Be Presented at the American Society of Hematology Annual Meeting (ASH) Business Wire +5.60%
08:54AM  3 Hammered Healthcare Stocks to Buy Now Motley Fool
07:42AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals Zacks
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
08:00AM  New Research: Key Drivers of Growth for Celgene, Briggs & Stratton, NewJersey Resources, RPM International, Anixter International, and Sensient Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-30-18 05:01PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
09:31AM  Is Beaten-Down Celgene Corporation a Buy Now? Motley Fool
06:33AM  Better Buy: Celgene Corporation vs. Gilead Sciences Motley Fool
Oct-29-18 05:45PM  Celgene (CELG) Dips More Than Broader Markets: What You Should Know Zacks
03:57PM  Celgene Beats and Raises, but It's All About the Pipeline Motley Fool
12:19PM  Edited Transcript of CELG earnings conference call or presentation 25-Oct-18 1:00pm GMT Thomson Reuters StreetEvents
08:57AM  The Zacks Analyst Blog Highlights: McDonald's, Thermo Fisher, Caterpillar, CSX and Celgene Zacks
Oct-26-18 04:30PM  Gilead Sciences Stock Is Back to Base Go Long InvestorPlace
10:45AM  Top Research Reports for McDonald's, Thermo Fisher & Caterpillar Zacks
08:34AM  Here's Why I'm Not Selling My Celgene Shares Motley Fool
07:00AM  Nearly half of the S&P 500 is in a bear market. Here's where to hide out CNBC
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. and Dragonfly Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM
MARIO ERNESTDirectorAug 09Sale92.3212,0001,107,88844,413Aug 13 04:05 PM
BARKER RICHARD WDirectorJun 17Option Exercise0.001,000012,846Jun 18 04:00 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033400Jun 18 04:00 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00334037,436Jun 18 04:00 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00334056,413Jun 18 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037501,250Jun 15 04:57 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375056,079Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037501,050Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441037,102Jun 15 04:13 PM
Friedman Michael ADirectorJun 15Option Exercise0.002,41300Jun 15 04:12 PM
Haller Julia ADirectorJun 14Option Exercise0.003000875Jun 15 04:57 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300055,704Jun 15 04:23 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.003000675Jun 15 04:17 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 15 04:16 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300034,661Jun 15 04:13 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 15 04:12 PM
COX CARRIE SMITHDirectorJun 12Option Exercise0.006,200030,080Jun 14 04:35 PM
CASEY MICHAEL DDirectorJun 07Option Exercise30.0127,750832,77827,750Jun 11 04:06 PM
CASEY MICHAEL DDirectorJun 07Sale78.7713,0001,024,0100Jun 11 04:06 PM
LOUGHLIN JAMES JDirectorJun 04Option Exercise30.0127,750832,77852,111Jun 05 04:15 PM
LOUGHLIN JAMES JDirectorJun 04Sale78.9617,7501,401,54034,361Jun 05 04:15 PM
Masoudi GeraldSEE REMARKSJun 01Option Exercise0.0015,000020,235Jun 05 04:09 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 09Buy82.601,20899,784187,316May 17 04:08 PM
Curran TerrieMay 04Option Exercise0.002,50007,507May 08 04:56 PM
VESSEY RUPERTMay 04Option Exercise0.0078103,731May 08 04:36 PM
KELLOGG PETER NMay 04Option Exercise0.003,500050,831May 08 04:34 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 04Option Exercise0.003,5000187,627May 08 04:30 PM
LOUGHLIN JAMES JDirectorMar 12Option Exercise27.189,250251,41533,611Mar 13 04:22 PM
LOUGHLIN JAMES JDirectorMar 12Sale92.019,250851,09324,361Mar 13 04:22 PM
MARIO ERNESTDirectorFeb 23Sale94.4913,3701,263,29855,404Feb 26 04:11 PM
KAPLAN GILLADirectorFeb 20Sale94.839,250877,17876,301Feb 20 05:02 PM
Smith Scott AndrewSee RemarksFeb 17Option Exercise0.007,283051,748Feb 20 05:03 PM
KELLOGG PETER NSee RemarksFeb 17Option Exercise0.007,283049,660Feb 20 05:03 PM
Alles Mark JSee RemarksFeb 17Option Exercise0.007,2830186,187Feb 20 05:00 PM
KAPLAN GILLADirectorFeb 15Option Exercise27.189,250251,41594,801Feb 20 05:02 PM
KAPLAN GILLADirectorFeb 15Sale95.999,250887,89885,551Feb 20 05:02 PM
Alles Mark JSee RemarksFeb 08Buy91.903,260299,594178,904Feb 08 04:47 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62305,623Feb 05 04:39 PM
Smith Scott AndrewSee RemarksDec 19Option Exercise0.003,410046,233Dec 20 04:05 PM
KELLOGG PETER NSee RemarksDec 19Option Exercise0.003,410044,145Dec 20 04:04 PM
Curran TerrieSee remarksDec 19Option Exercise0.001,76505,690Dec 20 04:03 PM
Alles Mark JSee RemarksDec 19Option Exercise0.004,5500177,738Dec 20 04:02 PM